Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Open-label, multicenter, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study.

Phase 1

Halozyme Therapeutics